1-5 of 5
Lisa Aurand
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Christopher Patriquin, Jun-Ho Jang, Lisa Aurand, Deepak Taneja, Andrew Magyar, Bradley Dain, Karoline Meagher, Lorah Perlee, Amal Souttou, Morag Griffin
Journal: Blood
Blood (2024) 144 (Supplement 1): 306.
https://doi.org/10.1182/blood-2024-194610
Published: 2024
Journal Articles

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Richard J. Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Kosalai Mohan, Brian Senk, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin
Journal: Blood
Blood (2023) 142 (Supplement 1): 2716.
https://doi.org/10.1182/blood-2023-188671
Published: 2023
Journal Articles

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Richard Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Bradley Dain, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin
Journal: Blood
Blood (2022) 140 (Supplement 1): 8174–8175.
https://doi.org/10.1182/blood-2022-166547
Published: 2022
Journal Articles

A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jun Ho Jang, Raymond Wong, Rodrigo Pavani, Lisa Aurand, Bradley Dain, Lorah Perlee, Amal Souttou, Jonathan Weyne, Richard Kelly
Journal: Blood
Blood (2022) 140 (Supplement 1): 8172–8173.
https://doi.org/10.1182/blood-2022-163236
Published: 2022
Journal Articles

Patient-Reported Outcomes from a Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Chris Hartford, Bradley Dain, Steven Sherman, Yi Zhang, Rodrigo Pavani, Lisa Aurand, Diana Rofail, Richard Kelly
Journal: Blood
Blood (2022) 140 (Supplement 1): 10849–10850.
https://doi.org/10.1182/blood-2022-163510
Published: 2022